Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Rese-cel’s nine-day CAR-T process reported strong safety and efficacy in autoimmune diseases, with over 90 patients treated and no IEC-HS events. Dual-source manufacturing and outpatient protocols are part of the scale-up plan.
Cabaletta’s rese-cel team cited a nine-day manufacturing process and strong safety profile, reporting over 90 patients treated with no IEC-HS events. Expansion into scleroderma and myositis is underway with dual manufacturing partnerships.